Suicide and self-harm risk nearly triple in people with restless leg syndrome
Restless legs syndrome was associated with a nearly tripled risk of suicide and self-harm in a new study led by Penn State researchers.
Aug 23, 2019
0
1141
Restless legs syndrome was associated with a nearly tripled risk of suicide and self-harm in a new study led by Penn State researchers.
Aug 23, 2019
0
1141
Small intestine bacterial overgrowth (SIBO) may be more prevalent among patients with restless legs syndrome (RLS), according to preliminary findings from a small, new study.
Jun 7, 2019
1
3942
An international research team led by investigators from Massachusetts General Hospital (MGH) and the University of Exeter Medical School has identified 57 gene regions associated with symptoms of insomnia. Their report, ...
Feb 25, 2019
0
109
New research published in the Journal of Physiology presents a breakthrough in the treatment of Restless Legs Syndrome (RLS).
Nov 14, 2018
0
9
Dear Mayo Clinic: Is restless legs syndrome hereditary? Is there an effective treatment, or does a diagnosis of RLS mean I will have it for life?
Sep 28, 2018
0
5
(HealthDay)—For patients with restless leg syndrome (RLS), the primary motor cortex (M1) exhibits hyperexcitability, which is associated with disease severity, according to a study published recently in Sleep Medicine.
Sep 7, 2018
0
3
Johns Hopkins Medicine researchers say new experiments using magnetic pulse brain stimulation on people with moderate to severe restless legs syndrome (RLS) have added to evidence that the condition is due to excitability ...
Aug 29, 2018
1
17
Up to eight out of 10 people living with a brain disorder remain untreated or inadequately treated, even though effective therapies exist. What are the barriers to optimal treatment? Is it really unaffordable to grant people ...
Jun 18, 2018
0
2
People with restless legs syndrome may have changes in a portion of the brain that processes sensory information, according to a study published in the April 25, 2018, online issue of Neurology, the medical journal of the ...
Apr 25, 2018
0
457
(HealthDay)—Ultragenyx Pharmaceutical Inc.'s Crysvita (burosumab-twza) has been approved by the U.S. Food and Drug Administration to treat adults and children ages 1 year and older with x-linked hypophosphatemia (XLH).
Apr 23, 2018
0
4